NEW YORK (GenomeWeb News) – Japanese drug firm Eisai has launched US subsidiary H3 Biomedicine with up to $200 million in funding to develop new oncology drugs based on patient genetic information.
Based in Cambridge, Mass., H3 Biomedicine aims to take a personalized medicine approach to developing such drugs by leveraging new insights into the genetic basis of cancer and advances in modern chemistry.